Abstract
The clinical significance of sIL-2R in solid tumors has still to be clarified. To further define the biological role of sIL-2R in cancer and their relation to chemotherapy, we have measured serum levels of sIL-2R and CD4/CD8 ratio in 45 patients with limited or metastatic solid tumor, 28 of whom had never received chemotherapy, whereas the other 17 had been previously treated with chemotherapy. sIL-2R were significantly higher in metastatic cancer patients than in the non-metastatic ones, while no difference was seen between patients treated and untreated with chemotherapy. Within the untreated group, sIL-2R mean values were significantly higher in patients with low CD4/CD8 ratio than in those with the normal one, while an opposite behavior was seen in patients previously treated with chemoterapy. The present study shows that cancer chemotherapy influences the release of sIL-2R and its relation to T lymphocyte subpopulations.
| Original language | English |
|---|---|
| Pages (from-to) | 131-133 |
| Number of pages | 3 |
| Journal | Journal of Biological Regulators and Homeostatic Agents |
| Volume | 3 |
| Issue number | 3 |
| Publication status | Published - 1989 |
ASJC Scopus subject areas
- Agricultural and Biological Sciences(all)
- Endocrinology
- Physiology
- Immunology
- Medicine (miscellaneous)
- Endocrinology, Diabetes and Metabolism
- Physiology (medical)